BRIEF-Almirall agrees for AstraZeneca to buy US and Canada rights for aclidinium bromide

Thu Feb 5, 2015 3:15am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Feb 5 (Reuters) - Almirall SA :

* Says agrees for AstraZeneca to acquire the US and Canada rights for aclidinium bromide from Actavis

* Says upon completion of transaction, AstraZeneca will own development and commercial rights in US and Canada to Tudorza Pressair for chronic obstructive pulmonary disease (COPD)

* Says AstraZeneca will assume development rights and obligations in US and Canada for LA40464, approved in the EU under the brand name Duaklir Genuair Source text for Eikon: Further company coverage: (Gdynia Newsroom)